IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

VALENZA, CARMINE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 818
EU - Europa 732
NA - Nord America 655
SA - Sud America 86
AF - Africa 26
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 2
Totale 2.321
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 637
DE - Germania 367
SG - Singapore 288
CN - Cina 231
IT - Italia 146
BD - Bangladesh 73
BR - Brasile 69
VN - Vietnam 68
HK - Hong Kong 60
SE - Svezia 49
RU - Federazione Russa 48
IN - India 36
FR - Francia 35
NL - Olanda 21
FI - Finlandia 19
CI - Costa d'Avorio 14
ID - Indonesia 12
GB - Regno Unito 10
CA - Canada 9
TR - Turchia 9
AR - Argentina 7
KR - Corea 7
PL - Polonia 7
ES - Italia 6
IQ - Iraq 6
JP - Giappone 6
UA - Ucraina 5
ZA - Sudafrica 5
AT - Austria 4
EC - Ecuador 4
EG - Egitto 4
PH - Filippine 4
PK - Pakistan 4
CH - Svizzera 3
CO - Colombia 3
IE - Irlanda 3
JM - Giamaica 3
VE - Venezuela 3
AZ - Azerbaigian 2
CZ - Repubblica Ceca 2
MX - Messico 2
NI - Nicaragua 2
PS - Palestinian Territory 2
RO - Romania 2
SA - Arabia Saudita 2
UZ - Uzbekistan 2
XK - ???statistics.table.value.countryCode.XK??? 2
AE - Emirati Arabi Uniti 1
AU - Australia 1
DK - Danimarca 1
DZ - Algeria 1
GR - Grecia 1
HN - Honduras 1
IL - Israele 1
KE - Kenya 1
KZ - Kazakistan 1
LT - Lituania 1
MY - Malesia 1
NO - Norvegia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PA - Panama 1
PT - Portogallo 1
TN - Tunisia 1
TW - Taiwan 1
Totale 2.321
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 343
Singapore 139
Ashburn 112
Dallas 98
Santa Clara 75
Hefei 66
San Jose 61
Hong Kong 47
Boardman 36
Beijing 32
Los Angeles 31
Council Bluffs 30
Milan 25
Ho Chi Minh City 24
Bengaluru 23
New York 19
Hanoi 18
Munich 15
Abidjan 14
Lauterbourg 14
Moscow 12
Shanghai 11
Buffalo 10
Chandler 9
Helsinki 9
Istanbul 7
Naples 7
Rome 7
Amsterdam 6
Guangzhou 6
Hyderabad 6
Seoul 6
São Paulo 6
Turku 6
Cangzhou 5
Rho 5
Tokyo 5
Turin 5
Altamura 4
Düsseldorf 4
Jakarta 4
Lappeenranta 4
Miano 4
Barnet 3
Brooklyn 3
Cairo 3
Chicago 3
Columbus 3
Da Nang 3
Dublin 3
Fuzhou 3
Gainesville 3
Johannesburg 3
Manaus 3
Messina 3
Orem 3
Pianoro 3
Quanzhou 3
Vienna 3
Warsaw 3
Zurich 3
Ankara 2
Baku 2
Barcelona 2
Belo Horizonte 2
Buon Ma Thuot 2
Bắc Ninh 2
Changsha 2
Des Moines 2
Hai Bà Trưng 2
Haiphong 2
Houston 2
Karachi 2
Kingston 2
Kyiv 2
Locate di Triulzi 2
Lyon 2
Managua 2
Manassas 2
Manila 2
Montreal 2
Mumbai 2
Nuremberg 2
Osasco 2
Phoenix 2
Praia Grande 2
Princeton 2
Pristina 2
Quận Ba 2
Quận Hai 2
Ragusa 2
Raubach 2
Reggio Emilia 2
Rio de Janeiro 2
Roubaix 2
Sant'Agata Li Battiati 2
Seattle 2
Seregno 2
Shenyang 2
Shijiazhuang 2
Totale 1.502
Salva come PNG Salva come JPEG
Nome #
Evolving treatment landscape of immunotherapy in breast cancer: current issues and future perspectives 191
Complex differential diagnosis between primary breast cancer and breast metastasis from egfr-mutated lung adenocarcinoma: Case report and literature review 185
Biomarkers for antibody-drug conjugates in solid tumors 184
Primary malignant phyllodes tumors of the breast: A retrospective analysis from a referral center 165
Metastasis-directed stereotactic radiotherapy and systemic treatment continuation for patients with oligoprogressive metastatic breast cancer 152
Cardiotoxicity of Agents Used in Patients With Breast Cancer 148
Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments 146
Germline BRCA pathogenic variants and hematologic adverse events in patients with ovarian carcinoma receiving PARP inhibitors: a retrospective cohort study 144
Histology-agnostic approvals for antibody-drug conjugates in solid tumours: is the time ripe? 143
The pathologic and genomic evolution of primary malignant phyllodes tumors of the breast: retrospective cohort study and case-control genomic analysis 137
Cyclin dependent kinase 4/6 inhibitors in early breast cancer: what is the role of Ki-67? 136
The immunogram of inflammatory breast cancer 130
Immune-Related Adverse Event Likelihood Score Identifies “Pure” IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population 124
The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer 99
PARP inhibitor resistant BRCA-mutated advanced breast cancer: current landscape and emerging treatments 99
Immune checkpoint inhibitors for patients with metastatic triple-negative inflammatory breast cancer (INCORPORATE): An international cohort study 94
New Concepts in Cardio-Oncology 21
Extendeond Endocrine Therapy and Survival for Breast Cancer Subtypes in Premenopausal Patients 16
Advancing Antibody-Drug Conjugates: Current Perspectives and Future Directions 13
Scientific highlights and perspectives from the International Inflammatory Breast Cancer Symposium 2025 12
Sacituzumab govitecan in the first-line treatment of triple-negative breast cancer: balancing therapeutic sequencing with patient-relevant benefits 11
Circulating tumor DNA: a biomarker for oncology drug development in phase I clinical trials? 10
Rechallenge with platinum-based chemotherapy in patients with platinum-resistant ovarian carcinoma: A cohort study 10
Beyond Boundaries in ERBB2-Positive Brain Metastatic Breast Cancer 10
Monitoring serum estradiol in premenopausal women with hormone receptor-positive breast cancer on adjuvant LHRH agonists 10
Role of Social Media for Medical Oncologists and Medical Oncology Fellows (SMARTY): An Italian Cross-Sectional Study 8
Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future Challenges 8
Metastasis-directed thermal ablation in patients with metastatic breast cancer and visceral oligoprogression or oligopersistence: a cohort study 8
The evolving landscape of hormone receptor-positive/HER2-negative metastatic breast cancer (EVOLVE): An Italian Delphi consensus report 8
From Dose-Finding to Dose-Optimization in Early-Phase oncology clinical trials 7
null 6
Circulating tumour DNA dynamics for assessment of molecular residual disease and for intercepting resistance in breast cancer 6
Positioning oral selective estrogen receptor degraders in patients with metastatic breast cancer 6
Bispecific Antibodies in Hematologic and Solid Tumors: Current Landscape and Therapeutic Advances 5
The triple negative breast cancer drugs graveyard: a review of failed clinical trials 2017-2022 4
Variant allele frequency: a decision-making tool in precision oncology? 4
Pembrolizumab and oral metronomic cyclophosphamide in patients with chest wall breast cancer (PERICLES): an immune-biomarker analysis of tumor infiltrating lymphocytes (TILs) and programmed cell death ligand protein 1 (PD-L1) 3
null 3
Emerging treatment landscape of non-muscle invasive bladder cancer 2
Treatment optimization in early triple negative breast cancer 1
Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor-Positive Breast Cancer: A Cohort Study 1
Awareness, Knowledge, and Treatment Patterns of Nonmetastatic Inflammatory Breast Cancer in Low- and Middle-Income Countries: The BRIDGES Study 1
Tumor Infiltrating Lymphocytes across Breast Cancer Subtypes: Current Issues for Biomarker Assessment 1
Totale 2.472
Salva come PNG Salva come JPEG
Categoria #
all - tutte 6.123
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.123
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202216 0 0 0 0 5 0 1 1 4 2 0 3
2022/202333 3 4 2 7 2 4 1 2 5 0 3 0
2023/2024296 9 3 7 5 10 8 26 28 15 42 74 69
2024/2025535 55 59 57 58 21 6 5 38 15 39 43 139
2025/20261.592 154 163 213 143 75 55 120 62 120 92 167 228
Totale 2.472